Aspirin prophylaxis for hereditary and acquired thrombotic thrombocytopenic purpura?

Am J Hematol. 2022 Aug;97(8):E304-E306. doi: 10.1002/ajh.26603. Epub 2022 Jun 7.

Authors

Bojing Shao¹, Sanober Nusrat², James N George^{2

3}, Lijun Xia¹

Affiliations

¹ Cardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA.
² Department of Medicine, College of Medicine, Hematology-Oncology Section, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.
³ Department of Biostatistics & Epidemiology, Hudson College of Public Health, Oklahoma City, Oklahoma, USA.

No abstract available

Publication types

Letter
Research Support, N.I.H., Extramural

MeSH terms

ADAMTS13 Protein
Analgesics
Aspirin / therapeutic use
Humans
Plasma Exchange
Purpura, Thrombotic Thrombocytopenic* / genetics
Purpura, Thrombotic Thrombocytopenic* / prevention & control

Substances

Analgesics
ADAMTS13 Protein
Aspirin

Supplementary concepts

Thrombotic thrombocytopenic purpura, acquired

Grants and funding

R01 HL149860/HL/NHLBI NIH HHS/United States